References
L-204

1. Fonseca R, Bergsagel PL, Drach J, et al. International myeloma working group molecular classification of multiple myeloma: spotlight review. *Leukemia.* 2009; 23(12):2210-2221.

2. Weinhold N, Heuck C, Rosenthal A, et al. The clinical value of molecular subtyping multiple myeloma using gene expression profiling. *Leukemia.* 2016;30(2):423-430.

3. Gerecke C, Fuhrmann S, Strifler S, et al. The diagnosis and treatment of multiple myeloma. *Dtsch Arztebl Int.* 2016; 113:470-476.

4. Munshi NC, Anderson KC, Bergsagel PL, et al. Consensus recommendations for risk stratification in multiple myeloma: report of the international myeloma workshop consensus panel 2. *Blood.* 2011; 117(18):4696-4700.

5. Hose D, Seckinger A, Jauch A, et al. The role of flueorescence in situ hybridization and gene expression profiling in myeloma risk stratification. *Srp Arh Celok Lek.* 2011 Dec;139(Suppl 2):84-89.

6. Boyle EM, Proszek PZ, Kaiser MF, et al. A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myeloma. *Genes Chromosomes Cancer.* 2015 Feb;54(2):91-98.

7. Mikhael JR, Dingli D, Roy V, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. *Mayo Clinic proceedings.* 2013 Apr;88(4):360-76.

8. Signal Genetics™. Multiple Myeloma Gene Expression Profile Report. MyPRS®. 2014. Available at: www.signalgenetics.com/sites/default/files/MyPRSExamplePatientReport.pdf.

9. Qu P, Barlogie B, Crowley J. Using a latent class model to refine risk stratification in multiple myeloma. *Stat Med.* 2015; 34(21):2971-2980.

10. National Comprehensive Cancer Network (NCCN). Multiple myeloma. Version 3.2017. Available at www.nccn.org.

11. Van Laar R, Flinchum R, Brown N, et al. Transplanting a gene expression signature for multiple myeloma prognosis into a robust high-throughput assay for clinical use. *BMC Medical Genomics.* 2014; 7:25.

12. Shaughnessy, JD, Jr., Zhan, F, Burington, BE, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. *Blood.* 2007;109:2276-2284.

13. Nair B, Shaughnessy JD, Zhou Y, et al. Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival. *Blood.* 2009; 113(26):6572-6575.

14. Kumar, SK, Uno H, Jacobus SJ, et al. Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone. *Blood.* 2011;118:4359-4362.